Meropenem, rifampicin and gentamicin combination therapy in a patient with complicated urinary tract infection caused by extreme drug-resistant P. aeruginosa.

European Journal of Hospital Pharmacy. Science and Practice
Aslınur AlbayrakEsin Şenol

Abstract

In this article, we report a case of a 25-year-old male patient who was under follow-up for nephrolithiasis and repeated urological interventions. His last operation was carried out 9 months ago for insertion of a double-J catheter. Pseudomonas aeruginosa, which is susceptible to only colistin treatment, was detected in the urine culture. Before the removal of the double-J catheter, colistin and ceftazidime antibiotics were started to prevent the risk of bloodstream infection. However, the treatment was stopped urgently due to signs of nephrotoxicity. His treatment was restarted with colistin 300 mg once as the initial loading dose, followed by 150 mg/day. However, this time, colistin neurotoxicity has developed and the treatment was again stopped. Meropenem 6 g/day, gentamicin 2 mg/kg and rifampicin 300 mg were prescribed. Negative urine culture was achieved on the fifth day of treatment.

References

Nov 24, 2005·Antimicrobial Agents and Chemotherapy·Vincent H TamElizabeth A Coyle
Mar 2, 2006·Critical Care : the Official Journal of the Critical Care Forum·Matthew E Falagas, Sofia K Kasiakou
Apr 11, 2013·Antimicrobial Agents and Chemotherapy·Karri A BauerDebra A Goff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Related Papers

The Lancet Infectious Diseases
Daniele Roberto Giacobbe
Pediatria
Y CHABBERT de LAJUDIE
Antibiotica Et Chemotherapia. Fortschritte. Advances. Progrès
H SCHOENENBERG
© 2021 Meta ULC. All rights reserved